107results about How to "Improve treatment adherence" patented technology

A method for characterizing a brain electrical signal comprising forming a temporo-spectral decomposition of the signal to form a plurality of time resolved frequency signal values, associating each instance of the signal value with a predetermined function approximating a neurological signal to form a table of coefficients collectively representative of the brain electrical signal.

The invention comprises componentry and devices for light therapy application to a patient in need thereof. The present invention relates to controllers for light therapy devices, light delivery elements, light guides, light guide arrangements configured to deliver personalized light therapy to one or more patients, with related componentry, dosage, and configurations of light therapy delivery elements (e.g., bandages, garments, braces, inserts etc.) suitable to deliver light therapy to one or more patient body areas and associated tissues, as well as sensors for monitoring treatment progress and dosage optimization. Methods of delivering light therapy to a patient and treatment of associated medical indications are also set out herein. Personalized LLLT dosage configurations and telemedicine LLLT treatment platforms and systems are also provided herein.

An antithrombotic drug is administered by a needle-free injection device for prevention or treatment of venous thromboembolism. In an embodiment, the needle-free injection device is a pre-filled, single-use, disposable device with antithrombotic medication and labeled regarding drug, dose and time of delivery.

The invention relates to an E-mental symptom fast screening and self-checking system for assisting diagnosis and treatment. The system comprises an initial interface, a scale selecting interface, a scale assessing interface and a detecting result interface. The scale selecting interface comprises four selectable scales including a QIDS-SR 16, an HCL-32, an MDQ and a PHQ-9, and the four scales are self-rating depression scales. The detecting result interface comprises grades, condition description, clinic prompt and an instruction. By means of the testing result, a patient can be guided to pertinently see a doctor, and the doctor can be assisted to carry out the diagnosis and treatment. The system can serve as a screening tool for bipolar disorder and other diseases and can also serve as a tool for monitoring the illness. The tablet personal computer technology serves as the basis, the system is simple in structure, and operation is easy and convenient due to the fact that input is achieved through a touch screen and a computer keyboard.

The invention belongs to the filed of medicine and discloses a pharmaceutical composition using fimasartan and rosuvastatin or medicinal salt thereof as active components, wherein a mass ratio of rosuvastatin or medicinal salt thereof to fimasartan is 1:0.25-250 and preferably 1:10-100. The pharmaceutical composition containing rosuvastatin medicinal salt thereof and fimasartan has obvious synergism on treating hypertension and complications thereof, low treatment cost, little side-effect and good clinic application prospect.

The invention discloses a mood state self-rating system based on an electronized POMS self-rating scale. The system comprises a smart phone and a background cloud server. The independently developed electronized POMS self-rating scale is installed in the smart phone, scale data sent by the smart phone is received by the background cloud server, a mood state evaluating algorithm is operated, and an obtained main mood state and the change rule thereof, different mood state daily change rules of a user, total mood quantitative evaluation and other results are sent to the smart phone and fed back to the user. The electronized self-rating scale is operated through a sliding block, a button and other assemblies, the easy and convenient operation is suitable for daily mental state evaluation of mental patients and further consultation patients suffering from depression, mania, anxiety and the like, the treatment compliance of the patients is improved, mental state evaluation services can be provided for normal users in the environments of families and communities, and the accessibility of mental health medical treatment services is improved.

The invention discloses an application of berberine in medicine for treating or preventing influenza virus. The application proves that berberine enjoys the good function of resisting influenza virus on MDCK cells infected by A-type influenza virus such as H5N1 and H3N2 and on A549 cells.Meanwhile, the berberine can kill influenza virus to a certain extent, prevent attack from the influenza virusand inhibit cells infected by the influenza virus; the berberine enjoys similar effect to amantadine, a positive control medicine; in addition, the berberine can well inhibit inflammatory responses triggered by the influenza virus and is disclosed to enjoy the prospect of being developed into the medicine for resisting the influenza virus.

The invention provides a composite peony seed oil self-emulsifying system composition and a preparation method thereof. The self-emulsifying system composition comprises composite peony seed oil, emulsifier and co-emulsifier, can further contain dispersant and/or solid adsorbent and can be prepared into oral formulations like soft capsules, liquid capsules, hard capsules and granules. The self-emulsifying system composition after entering a body can self-microemulsify under action of gastrointestinal liquid to form emulsified liquid, and absorption of the self-emulsifying system composition in a gastrointestinal tract can be promoted, so that bioavailability and efficacy of the composite peony seed oil self-emulsifying system composition are improved. The self-emulsifying system composition is low in cost, high in stability, convenient to store and transport and little in side effect, and compliance of a patient with oral formulation medicine based on the composite peony seed oil self-emulsifying system composition can be improved.

The invention discloses application of pomegranate in preparing a medicament for treating or preventing hepatitis B virus (HBV) infection. The application is implemented through the following steps: detecting the cytotoxicity of each pomegranate sourced medicament to HepG2.117, wherein the CC50 of punicalagin, gallic acid and punicalin is sequentially more than 500mu M, 334mu M and 218.86mu M; and then detecting the effects of the punicalagin, ellagic acid, gallic acid and punicalin to HBeAg and HBsAg, and the effect of punicalagin to DNA (deoxyribonucleic acid) and RNA (ribonucleic acid) of virus. Results indicate that the four compounds can be used for inhibiting HBeAg and HBsAg, wherein the punicalagin can be used for remarkably reducing the cccDNA (covalently closed circular DNA). The punicalagin can be used for remarkably reducing the contents of HBeAg and cccDNA in an HepG2.2.15 cell, and does not have effect to the total HBV DNA in the cell, which indicates that the punicalagin takes the cccDNA as a target to directly clear the cccDNA in a liver cell. Currently, the anti-HBV infection medicament in clinical treatment cannot directly act on the cccDNA, and cannot completely remove the virus. Experiment results disclose that the medicament has the prospect of being developed into anti-HBV infection medicaments.

The invention discloses the application of berberine in medicament for treating hepatitis B virus infection. In the invention, adopting an HepG2.2.15 cell model for the in vitro selection of anti-hepatitis B virus medicine, preliminarily selecting the effect of the medicament by measuring the difference of HBeAg and HBsAg expression volumn in supernatant fluid of the cell after administration, andfurther determining the effectiveness of the medicine by studying the inhibitory effect of the HBV DNA reproduction level (ccc DNA) in the HepG2.2.15 cell by the medicament. Meanwhile, the influenceon the reproduction of the hepatitis B virus by the transcriptional level of the medicine is studied according to the activity inhibitory effect to HBV viral promoters by the medicine, and key HBV cis-regulatory elements sensitive to the antivirus medicine are found. A pivotal cellular signal transduction pathway possibly participating the transcription reproduction for inhibiting viruses by the medicine is analyzed and verified on the basis, the antivirus molecular mechanism of the medicament is further studied, and the medicament is indicated to be developed and applied to clinical treatmentas an anti-hepatitis B effective medicament.

The invention relates to the field of medicine, in particular to a pharmaceutical composition for treating radioactive oral mucositis and a preparation method thereof. The pharmaceutical composition is prepared from the following raw materials in parts by weight: 15-40 parts of hairyvein agrimony, 15-40 parts of radix glehniae, 15-40 parts of radix ophiopogonis, 15-40 parts of astragalus membranaceus, 15-40 parts of honeysuckle, 1-8 parts of juncus effuses, 5-20 parts of flos magnoliae liliflorae, 3-10 parts of raw liquorice and 3-10 parts of mint. According to the invention, the traditional Chinese medicines such as agrimonia pilosa ledeb, adenophora stricta and the like are reasonably matched by adopting a method for qi tonifying, yin nourishing, stasis removing and detoxifying, and aretaken by adopting a specific compound granule process and a buccal administration method, so that the severity of radioactive oral mucositis can be reduced, pain can be relieved, the radiotherapy intake of a patient can be improved, and the treatment compliance can be improved.

The invention provides a peony seed oil self-emulsifying system composition and a preparation method thereof. The self-emulsifying system composition comprises peony seed oil, an emulsifier and a co-emulsifier, further comprises a dispersing agent and/or a solid adsorbing agent and can be prepared into soft capsules, liquid capsules, hard capsules, granules and other oral dosage forms. After the self-emulsifying system composition enters the human body, self-micro-emulsification can be performed under the effect of gastrointestinal fluid, and absorption of the composition in the stomach and intestinal tracts can be promoted, so that the biological availability and effects of the peony seed oil self-emulsifying system composition are improved, side effects are small, and the treatment compliance of a patient for oral dosage medicine based on the peony seed oil self-emulsifying system composition can be improved.

The invention discloses application of usnic acid (UA) in anti-influenza virus medicaments. The invention shows that the usnic acid has a certain anti-influenza virus function in vitro on MDCK cells and A549 cells infected by influenza A viruses, such as H5N1, H3N2 and the like. The impact effect of the medicaments applying the usnic acid relatively approaches that of a positive control medicament, namely amantadine; in addition, the usnic acid has better inhibiting effect on inflammatory reaction induced by the influenza viruses, which exposes that the medicaments applying the usnic acid have the prospect of being developed into anti-influenza virus medicaments.

The invention relates to the technical field of ophthalmic dosage forms and medical materials, and relates to a voriconazole-coated carrageenan corneal contact lens which is prepared by the following components according to the content: sequentially adding a silver salt aqueous solution and a voriconazole solution into a carrageenan aqueous solution, wherein the mass volume ratio of the carrageenan aqueous solution to the silver salt aqueous solution to the voriconazole solution is 10 g: (5-15) microliter: (7-13) microliter, the mass percent concentration of the carrageenan aqueous solution is 0.99-10%, the voriconazole solution is a voriconazole DMSO solution with the mass concentration of 0.1-5 mg/microliter, and the silver salt aqueous solution is a silver nitrate aqueous solution with the molar concentration of 0.1 mol/liter; the added silver ions can promote gelation of carrageenan, and the silver elementary substance can kill fungi, so that the dosage of voriconazole is reduced, the drug release time can be prolonged to 24 hours, the frequency of eye administration is reduced, the local eye stimulation symptom is relieved and the treatment effect on fungal keratitis is improved.

The invention discloses a disease information reminding method, a disease information reminding system and a disease information reminding device. The method comprises the steps: obtaining the medicalrecord information of a patient, and obtaining a medication prescription list; obtaining medicine taking time according to the medicine taking prescription list in the medical record information, andsending medicine taking reminding information and medicine taking supervision information when the medicine taking time is reached; obtaining the medicine getting time according to the medication prescription list in the medical record information, and sending medicine getting reminding information and medicine getting supervision information when the medicine getting time is reached. Therefore,the medical record information is automatically obtained and then the medicine taking time and the medicine taking time are obtained. The medicine taking reminding information and the medicine takingreminding information are sent to the patient in real time. Meanwhile, the medicine taking supervision information and the medicine taking supervision information are sent to a supervisor, so that thepatient and the supervisor can know the medicine taking and taking information in time. The treatment compliance of the patient is effectively improved, and the cure rate is improved. The manual writing workload of a doctor is greatly reduced. The information gathering and consulting are facilitated. The method can be widely applied to hospital information management.

The invention relates to a method for altering the release characteristics of a long acting drug delivery device containing at least two drugs in different segments, wherein the segments are arranged to a specific sequence. The invention furthermore relates to a drug delivery device with reduced initial burst containing two different drugs in different segments. The invention further relates to a delivery device manufactured according to the a.m. method and its use in contraception and gynecological therapies.

The invention provides a photodynamic diagnosis and therapy integrated alimentary canal capsule endoscopy, and belongs to the technical field of medical apparatus and instruments. The capsule endoscopy includes a camera-shooting system, a control system, a battery and a communication system; and the camera-shooting system includes a fluorescent camera, diagnosis LED light sources and treatment LEDlight sources. According to the capsule endoscopy, only a camera-shooting system of an existing magnetically controlled endoscope capsule system needs to be improved, a common optical photography system is replaced with a fluorescent camera-shooting system, and extra equipment does not need to be increased, so that the capsule endoscopy is strong in adaptability; the integration of the diagnosisand therapy on the internal cavities of human bodies can be realized, and one-time accomplishment of photodynamic diagnosis and therapy can be realized as well; as patients has no pain during the treatment with the provided capsule endoscopy, the treatment compliance of the patients can be greatly enhanced; and the provided capsule endoscopy can realize repeated diagnosis/therapy and can detect the treatment processes of the patients.

The invention discloses an oral medicine composition for treating obesity or vascular hypertension, and belongs to the field of medicine. The medicine composition comprises Orlistat or Cetilista and active ingredients of dipine medicine. In the medicine composition, the use amount of Orlistat or Cetilista and dipine medicine is greatly reduced; particularly, a sustained-release capsule prepared from the medicinal composition can achieve the treatment effect after being taken once a day only, so that the benefit/cost is increased, the patient compliance is improved, and the social value is higher.

The invention discloses an application of Lanosta-7,9(11),24-trien-3-one 15,26-dihydroxy in preparation of medicaments for preventing and/or treating enterovirus 71 infection. The invention confirms that the Lanosta-7,9(11),24-trien-3-one 15,26-dihydroxy has good antiviral effect in in-vitro enterovirus 71 (EV 71) infection cell tests. Meanwhile, the Lanosta-7,9(11),24-trien-3-one 15,26-dihydroxyhas certain killing effect on enterovirus 71 (EV 71), can prevent enterovirus 71 (EV 71) infection, has good treating effect on enterovirus 71 (EV 71) infected cells, has good inhibition effect on viral replication, and has more significant effect than a positive control medicament of ribavirin. In addition, the Lanosta-7,9(11),24-trien-3-one 15,26-dihydroxy has good inhibition effect on inflammation responses caused by enterovirus 71 (EV 71), which reveals that the Lanosta-7,9(11),24-trien-3-one 15,26-dihydroxy has the prospect of being developed into anti-enterovirus 71 (EV 71) medicaments.